Application of quantitative proteomics technologies to the biomarker discovery pipeline for multiple sclerosis

Proteomics - Clinical Applications

Volumn 7, Issue 1-2, 2013, Pages 91-108

  Dagley, Laura F ^a,b   Emili, Andrew ^b   Purcell, Anthony W ^a,c  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF TORONTO   (Canada)

^c MONASH UNIVERSITY   (Australia)

Author keywords

Biomarker discovery; Experimental autoimmune encephalomyelitis; MS; Multiple sclerosis; Quantitative proteomics

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; ALPHA 1 ANTITRYPSIN; ALPHA 2 MACROGLOBULIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN E; BETA 2 MICROGLOBULIN; BEVICAN CORE PROTEIN; BIOLOGICAL MARKER; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; CHITINASE LIKE 3 PROTEIN; CHROMOGRANIN A; CLUSTERIN; COMPLEMENT COMPONENT C3; CONACTIN 1; FETUIN A; FIBULIN 1; GELATINASE A; GLIAL FIBRILLARY ACIDIC PROTEIN; GLYCEROPHOSPHOINOSITOL INOSITOLPHOSPHODIESTERASE; HEMOPEXIN; LIPOCORTIN 5; PROTEIN DISULFIDE ISOMERASE; PROTEIN DISULFIDE ISOMERASE 3; SEROTRANSFERRIN; T KINNOGEN 1; THY 1 MEMBRANE GLYCOPROTEIN; UNCLASSIFIED DRUG; VIMENTIN; VITAMIN D BINDING PROTEIN; ZINC ALPHA 2 GLYCOPROTEIN;

ALLERGIC ENCEPHALOMYELITIS; BLOOD BRAIN BARRIER; CEREBROSPINAL FLUID; DISEASE MARKER; GOLD STANDARD; HUMAN; INTERMETHOD COMPARISON; ISOTOPE LABELING; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MULTIPLE SCLEROSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOGENESIS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN CONTENT; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEOMICS; REPRODUCIBILITY; REVIEW; UNINDEXED SEQUENCE; VALIDITY;

ANIMALS; BIOLOGICAL MARKERS; DISEASE PROGRESSION; HUMANS; MASS SPECTROMETRY; MULTIPLE SCLEROSIS; PROTEOMICS;

ANIMALIA;

EID: 84872718792     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201200104     Document Type: Review

References (187)

1. Weinshenker, B. G., Epidemiology of multiple sclerosis. Neurol. Clin. 1996, 14, 291-308.
2. Noseworthy, J. H., Lucchinetti, C., Rodriguez, M., Weinshenker, B. G., Multiple sclerosis. N. Engl. J. Med. 2000, 343, 938-952.
3. Beeson, P. B., Age and sex associations of 40 autoimmune diseases. Am. J. Med. 1994, 96, 457-462.
4. Compston, A., Coles, A., Multiple sclerosis. Lancet 2002, 359, 1221-1231.
5. Ebers, G. C., Bulman, D. E., Sadovnick, A. D., Paty, D. W. et al., A population-based study of multiple sclerosis in twins. N Engl J Med 1986, 315, 1638-1642.
6. Willer, C. J., Dyment, D. A., Risch, N. J., Sadovnick, A. D., Ebers, G. C., Twin concordance and sibling recurrence rates in multiple sclerosis. Proc. Natl. Acad. Sci. USA 2003, 100, 12877-12882.
7. Mumford, C. J., Wood, N. W., Kellar-Wood, H., Thorpe, J. W. et al., The British Isles survey of multiple sclerosis in twins. Neurology 1994, 44, 11-15.
8. Carton, H., Vlietinck, R., Debruyne, J., De Keyser, J. et al., Risks of multiple sclerosis in relatives of patients in Flanders, Belgium. J. Neurol. Neurosurg. Psychiatry 1997, 62, 329-333.
9. Robertson, N. P., Clayton, D., Fraser, M., Deans, J., Compston, D. A., Clinical concordance in sibling pairs with multiple sclerosis. Neurology 1996, 47, 347-352.
10. Ebers, G. C., Sadovnick, A. D., Risch, N. J., A genetic basis for familial aggregation in multiple sclerosis. Canadian Collaborative Study Group. Nature 1995, 377, 150-151.
11. Compston, D. A., Batchelor, J. R., McDonald, W. I., B-lymphocyte alloantigens associated with multiple sclerosis. Lancet 1976, 2, 1261-1265.
12. Ebers, G. C., Kukay, K., Bulman, D. E., Sadovnick, A. D. et al., A full genome search in multiple sclerosis. Nat. Genet. 1996, 13, 472-476.
13. Haines, J. L., Ter-Minassian, M., Bazyk, A., Gusella, J. F. et al., A complete genomic screen for multiple sclerosis underscores a role for the major histocompatability complex. The multiple sclerosis genetics group. Nat. Genet. 1996, 13, 469-471.
14. Terasaki, P. I., Park, M. S., Opelz, G., Ting, A., Multiple sclerosis and high incidence of a B lymphocyte antigen. Science 1976, 193, 1245-1247.
15. Marrosu, M. G., Muntoni, F., Murru, M. R., Costa, G. et al., HLA-DQB1 genotype in Sardinian multiple sclerosis: evidence for a key role of DQB1*0201 and*0302 alleles. Neurology 1992, 42, 883-886.
16. Olerup, O., Hillert, J., HLA class II-associated genetic susceptibility in multiple sclerosis: a critical evaluation. Tissue Antigens 1991, 38, 1-15.
17. Haines, J. L., Terwedow, H. A., Burgess, K., Pericak-Vance, M. A. et al., Linkage of the MHC to familial multiple sclerosis suggests genetic heterogeneity. The multiple sclerosis genetics group. Hum. Mol. Genet. 1998, 7, 1229-1234.
18. Gregory, S. G., Schmidt, S., Seth, P., Oksenberg, J. R. et al., Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis. Nat. Genet. 2007, 39, 1083-1091.
19. Hafler, D. A., Compston, A., Sawcer, S., Lander, E. S. et al., Risk alleles for multiple sclerosis identified by a genomewide study. N. Engl. J. Med. 2007, 357, 851-862.
20. Lundmark, F., Duvefelt, K., Iacobaeus, E., Kockum, I. et al., Variation in interleukin 7 receptor alpha chain (IL7R) influences risk of multiple sclerosis. Nat. Genet. 2007, 39, 1108-1113.
21. Gale, C. R., Martyn, C. N., Migrant studies in multiple sclerosis. Prog. Neurobiol. 1995, 47, 425-448.
22. Cepok, S., Zhou, D., Srivastava, R., Nessler, S. et al., Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis. J. Clin. Invest. 2005, 115, 1352-1360.
23. Levin, L. I., Munger, K. L., Rubertone, M. V., Peck, C. A. et al., Temporal relationship between elevation of Epstein-Barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis. JAMA 2005, 293, 2496-2500.
24. Ascherio, A., Munger, K. L., Lennette, E. T., Spiegelman, D. et al., Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study. JAMA 2001, 286, 3083-3088.
25. Soldan, S. S., Berti, R., Salem, N., Secchiero, P. et al., Association of human herpes virus 6 (HHV-6) with multiple sclerosis: increased IgM response to HHV-6 early antigen and detection of serum HHV-6 DNA. Nat. Med. 1997, 3, 1394-1397.
26. Ascherio, A., Munger, K. L., Simon, K. C., Vitamin D and multiple sclerosis. Lancet Neurol. 2010, 9, 599-612.
27. Kurtzke, J. F., Geography in multiple sclerosis. J. Neurol. 1977, 215, 1-26.
28. Hammond, S. R., McLeod, J. G., Millingen, K. S., Stewart-Wynne, E. G. et al., The epidemiology of multiple sclerosis in three Australian cities: Perth, Newcastle and Hobart. Brain 1988, 111 (Pt 1), 1-25.
29. van der Mei, I. A. F., Ponsonby, A. L., Dwyer, T., Blizzard, L. et al., Past exposure to sun, skin phenotype, and risk of multiple sclerosis: case-control study. BMJ 2003, 327, 316-321.
30. Munger, K. L., Zhang, S. M., O'Reilly, E., Hernan, M. A. et al., Vitamin D intake and incidence of multiple sclerosis. Neurology 2004, 62, 60-65.
31. Munger, K. L., Levin, L. I., Hollis, B. W., Howard, N. S., Ascherio, A., Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006, 296, 2832-2838.
32. Soilu-Hanninen, M., Laaksonen, M., Laitinen, I., Eralinna, J. P. et al., A longitudinal study of serum 25-hydroxyvitamin D and intact parathyroid hormone levels indicate the importance of vitamin D and calcium homeostasis regulation in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 2008, 79, 152-157.
33. Deluca, H. F., Cantorna, M. T., Vitamin D: its role and uses in immunology. FASEB J. 2001, 15, 2579-2585.
34. Bo, L., Geurts, J. J., Mork, S. J., van der Valk, P., Grey matter pathology in multiple sclerosis. Acta Neurol. Scand. Suppl. 2006, 183, 48-50.
35. McDonald, W. I., Compston, A., Edan, G., Goodkin, D. et al., Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann. Neurol. 2001, 50, 121-127.
36. Weiner, H. L., Guttmann, C. R., Khoury, S. J., Orav, E. J. et al., Serial magnetic resonance imaging in multiple sclerosis: correlation with attacks, disability, and disease stage. J. Neuroimmunol. 2000, 104, 164-173.
37. Hauser, S. L., Oksenberg, J. R., The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron 2006, 52, 61-76.
38. Gonen, O., Moriarty, D. M., Li, B. S., Babb, J. S. et al., Relapsing-remitting multiple sclerosis and whole-brain N-acetylaspartate measurement: evidence for different clinical cohorts initial observations. Radiology 2002, 225, 261-268.
39. Trapp, B. D., Nave, K. A., Multiple sclerosis: an immune or neurodegenerative disorder? Annu. Rev. Neurosci. 2008, 31, 247-269.
40. Confavreux, C., Vukusic, S., Age at disability milestones in multiple sclerosis. Brain 2006, 129, 595-605.
41. Miller, D. H., Leary, S. M., Primary-progressive multiple sclerosis. Lancet Neurol. 2007, 6, 903-912.
42. Kutzelnigg, A., Faber-Rod, J. C., Bauer, J., Lucchinetti, C. F. et al., Widespread demyelination in the cerebellar cortex in multiple sclerosis. Brain Pathol. 2007, 17, 38-44.
43. Kutzelnigg, A., Lucchinetti, C. F., Stadelmann, C., Bruck, W. et al., Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005, 128, 2705-2712.
44. Bronnum-Hansen, H., Koch-Henriksen, N., Stenager, E., Trends in survival and cause of death in Danish patients with multiple sclerosis. Brain 2004, 127, 844-850.
45. Bielekova, B., Martin, R., Multiple sclerosis: immunotherapy. Curr. Treat. Options Neurol. 1999, 1, 201-220.
46. Ibrahim, S. M., Gold, R., Genomics, proteomics, metabolomics: what is in a word for multiple sclerosis? Curr. Opin. Neurol. 2005, 18, 231-235.
47. Kappos, L., Achtnichts, L., Dahlke, F., Kuhle, J. et al., Genomics and proteomics: role in the management of multiple sclerosis. J. Neurol. 2005, 252 (Suppl 3), iii21-iii27.
48. Rosenling, T., Attali, A., Luider, T. M., Bischoff, R., The experimental autoimmune encephalomyelitis model for proteomic biomarker studies: from rat to human. Clinica chimica acta; international journal of clinical chemistry 2011, 412, 812-822.
49. Bielekova, B., Martin, R., Development of biomarkers in multiple sclerosis. Brain 2004, 127, 1463-1478.
50. Harris, V. K., Sadiq, S. A., Disease biomarkers in multiple sclerosis: potential for use in therapeutic decision making. Mol Diagn Ther 2009, 13, 225-244.
51. Andersson, M., Alvarez-Cermeño, J., Bernardi, G., Cogato, I. et al., Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report. J. Neurol. Neurosurg. Psychiatry 1994, 57, 897-902.
52. Freedman, M. S., Thompson, E. J., Deisenhammer, F., Giovannoni, G. et al., Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement. Arch. Neurol. 2005, 62, 865-870.
53. Tumani, H., Hartung, H. P., Hemmer, B., Teunissen, C. et al., Cerebrospinal fluid biomarkers in multiple sclerosis. Neurobiol. Dis. 2009, 35, 117-127.
54. Joseph, F. G., Hirst, C. L., Pickersgill, T. P., Ben-Shlomo, Y. et al., CSF oligoclonal band status informs prognosis in multiple sclerosis: a case control study of 100 patients. J. Neurol. Neurosurg. Psychiatry 2009, 80, 292-296.
55. Miller, D., Barkhof, F., Montalban, X., Thompson, A., Filippi, M., Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol. 2005, 4, 281-288.
56. Ransohoff, R. M., Kivisakk, P., Kidd, G., Three or more routes for leukocyte migration into the central nervous system. Nat. Rev. Immunol. 2003, 3, 569-581.
57. Rivers, T. M., Sprunt, D. H., Berry, G. P., Observations on attempts to produce acute disseminated encephalomyelitis in monkeys. J. Exp. Med. 1933, 58, 39-53.
58. Steinman, L., Zamvil, S. S., How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis? Ann. Neurol. 2006, 60, 12-21.
59. Gold, R., Hartung, H.-P., Toyka, K. V., Animal models for autoimmune demyelinating disorders of the nervous system. Mol. Med. Today 2000, 6, 88-91.
60. Ben-Nun, A., Wekerle, H., Cohen, I. R., The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis. Eur. J. Immunol. 1981, 11, 195-199.
61. Munoz, J. J., Bernard, C. C., Mackay, I. R., Elicitation of experimental allergic encephalomyelitis (EAE) in mice with the aid of pertussigen. Cell Immunol. 1984, 83, 92-100.
62. Hashim, G. A., Sharpe, R. D., Carvalho, E., Stevens, L. E., The development of experimental allergic encephalomyelitis with immunizing doses of myelin basic protein. Proc. Soc. Exp. Biol. Med. 1975, 149, 646-651.
63. Martenson, R. E., Deibler, G. E., Kies, M. W., Myelin basic proteins of the rat central nervous system. Purification, encephalitogenic properties, and amino acid compositions. Biochim. Biophys. Acta 1970, 200, 353-362.
64. Einstein, E. R., Robertson, D. M., Dicaprio, J. M., Moore, W., The isolation from bovine spinal cord of a homogeneous protein with encephalitogenic activity. J. Neurochem. 1962, 9, 353-361.
65. Kuchroo, V. K., Sobel, R. A., Laning, J. C., Martin, C. A. et al., Experimental allergic encephalomyelitis mediated by cloned T cells specific for a synthetic peptide of myelin proteolipid protein. Fine specificity and T cell receptor V beta usage. J. Immunol. 1992, 148, 3776-3782.
66. Mendel, I., Kerlero de Rosbo, N., Ben-Nun, A., A myelin oligodendrocyte glycoprotein peptide induces typical chronic experimental autoimmune encephalomyelitis in H-2b mice: fine specificity and T cell receptor V beta expression of encephalitogenic T cells. Eur. J. Immunol. 1995, 25, 1951-1959.
67. Bernard, C. C. A., Johns, T. G., Slavin, A., Ichikawa, M. et al., Myelin oligodendrocyte glycoprotein: a novel candidate autoantigen in multiple sclerosis. J. Mol. Med. 1997, 75, 77-88.
68. Storch, M. K., Stefferl, A., Brehm, U., Weissert, R. et al., Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of multiple sclerosis pathology. Brain Pathol. 1998, 8, 681-694.
69. Stefferl, A., Brehm, U., Linington, C., The myelin oligodendrocyte glycoprotein (MOG): a model for antibody-mediated demyelination in experimental autoimmune encephalomyelitis and multiple sclerosis. J. Neural. Transm. Suppl. 2000, 58, 123-133.
70. Gold, R., Linington, C., Lassmann, H., Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 2006, 129, 1953-1971.
71. Sriram, S., Steiner, I., Experimental allergic encephalomyelitis: a misleading model of multiple sclerosis. Ann. Neurol. 2005, 58, 939-945.
72. Ransohoff, R. M., Animal models of multiple sclerosis: the good, the bad and the bottom line. Nat. Neurosci. 2012, 15, 1074-1077.
73. Teitelbaum, D., Meshorer, A., Hirshfeld, T., Arnon, R., Sela, M., Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur. J. Immunol. 1971, 1, 242-248.
74. Yednock, T. A., Cannon, C., Fritz, L. C., Sanchez-Madrid, F. et al., Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 1992, 356, 63-66.
75. Hammack, B. N., Fung, K. Y., Hunsucker, S. W., Duncan, M. W. et al., Proteomic analysis of multiple sclerosis cerebrospinal fluid. Mult. Scler. 2004, 10, 245-260.
76. Chiasserini, D., Di Filippo, M., Candeliere, A., Susta, F. et al., CSF proteome analysis in multiple sclerosis patients by two-dimensional electrophoresis. Eur. J. Neurol. 2008, 15, 998-1001.
77. Ottervald, J., Franzen, B., Nilsson, K., Andersson, L. I. et al., Multiple sclerosis: identification and clinical evaluation of novel CSF biomarkers. J. Proteomics 2010, 73, 1117-1132.
78. Lehmensiek, V., Sussmuth, S. D., Tauscher, G., Brettschneider, J. et al., Cerebrospinal fluid proteome profile in multiple sclerosis. Mult. Scler. 2007, 13, 840-849.
79. Tumani, H., Lehmensiek, V., Rau, D., Guttmann, I. et al., CSF proteome analysis in clinically isolated syndrome (CIS): candidate markers for conversion to definite multiple sclerosis. Neurosci. Lett. 2009, 452, 214-217.
80. Stoop, M. P., Dekker, L. J., Titulaer, M. K., Burgers, P. C. et al., Multiple sclerosis-related proteins identified in cerebrospinal fluid by advanced mass spectrometry. Proteomics 2008, 8, 1576-1585.
81. Stoop, M. P., Dekker, L. J., Titulaer, M. K., Lamers, R. J. et al., Quantitative matrix-assisted laser desorption ionization-fourier transform ion cyclotron resonance (MALDI-FT-ICR) peptide profiling and identification of multiple-sclerosis-related proteins. J. Proteome Res. 2009, 8, 1404-1414.
82. Stoop, M. P., Singh, V., Dekker, L. J., Titulaer, M. K. et al., Proteomics comparison of cerebrospinal fluid of relapsing remitting and primary progressive multiple sclerosis. PLoS One 2010, 5, e12442.
83. Noben, J. P., Dumont, D., Kwasnikowska, N., Verhaert, P. et al., Lumbar cerebrospinal fluid proteome in multiple sclerosis: characterization by ultrafiltration, liquid chromatography, and mass spectrometry. J. Proteome Res. 2006, 5, 1647-1657.
84. Comabella, M., Fernandez, M., Martin, R., Rivera-Vallve, S. et al., Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis. Brain 2010, 133, 1082-1093.
85. Gorg, A., Weiss, W., Dunn, M. J., Current two-dimensional electrophoresis technology for proteomics. Proteomics 2004, 4, 3665-3685.
86. Molloy, M. P., Two-dimensional electrophoresis of membrane proteins using immobilized pH gradients. Anal. Biochem. 2000, 280, 1-10.
87. Gorg, A., Obermaier, C., Boguth, G., Harder, A. et al., The current state of two-dimensional electrophoresis with immobilized pH gradients. Electrophoresis 2000, 21, 1037-1053.
88. Timperman, A. T., Aebersold, R., Peptide electroextraction for direct coupling of in-gel digests with capillary LC-MS/MS for protein identification and sequencing. Anal. Chem. 2000, 72, 4115-4121.
89. Unlü, M., Morgan, M. E., Minden, J. S., Difference gel electrophoresis: a single gel method for detecting changes in protein extracts. Electrophoresis 1997, 18, 2071-2077.
90. Alban, A., David, S. O., Bjorkesten, L., Andersson, C. et al., A novel experimental design for comparative two-dimensional gel analysis: two-dimensional difference gel electrophoresis incorporating a pooled internal standard. Proteomics 2003, 3, 36-44.
91. Bondarenko, P. V., Chelius, D., Shaler, T. A., Identification and relative quantitation of protein mixtures by enzymatic digestion followed by capillary reversed-phase liquid chromatography-tandem mass spectrometry. Anal. Chem. 2002, 74, 4741-4749.
92. Chelius, D., Bondarenko, P. V., Quantitative profiling of proteins in complex mixtures using liquid chromatography and mass spectrometry. J. Proteome Res. 2002, 1, 317-323.
93. Liu, H., Sadygov, R. G., Yates, J. R., 3rd, A model for random sampling and estimation of relative protein abundance in shotgun proteomics. Anal. Chem. 2004, 76, 4193-4201.
94. Old, W. M., Meyer-Arendt, K., Aveline-Wolf, L., Pierce, K. G. et al., Comparison of label-free methods for quantifying human proteins by shotgun proteomics. Mol. Cell Proteomics 2005, 4, 1487-1502.
95. Colinge, J., Chiappe, D., Lagache, S., Moniatte, M., Bougueleret, L., Differential proteomics via probabilistic peptide identification scores. Anal. Chem. 2005, 77, 596-606.
96. Florens, L., Carozza, M. J., Swanson, S. K., Fournier, M. et al., Analyzing chromatin remodeling complexes using shotgun proteomics and normalized spectral abundance factors. Methods 2006, 40, 303-311.
97. Zybailov, B., Mosley, A. L., Sardiu, M. E., Coleman, M. K. et al., Statistical analysis of membrane proteome expression changes in Saccharomyces cerevisiae. J. Proteome Res. 2006, 5, 2339-2347.
98. Zybailov, B. L., Florens, L., Washburn, M. P., Quantitative shotgun proteomics using a protease with broad specificity and normalized spectral abundance factors. Mol. Biosyst. 2007, 3, 354-360.
99. Ishihama, Y., Oda, Y., Tabata, T., Sato, T. et al., Exponentially modified protein abundance index (emPAI) for estimation of absolute protein amount in proteomics by the number of sequenced peptides per protein. Mol. Cell Proteomics 2005, 4, 1265-1272.
100. Rappsilber, J., Ryder, U., Lamond, A. I., Mann, M., Large-scale proteomic analysis of the human spliceosome. Genome Res. 2002, 12, 1231-1245.
101. Gygi, S. P., Rist, B., Gerber, S. A., Turecek, F. et al., Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat. Biotechnol. 1999, 17, 994-999.
102. Ross, P. L., Huang, Y. N., Marchese, J. N., Williamson, B. et al., Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol. Cell Proteomics 2004, 3, 1154-1169.
103. Aggarwal, K., Choe, L. H., Lee, K. H., Shotgun proteomics using the iTRAQ isobaric tags. Brief Funct. Genomic Proteomic. 2006, 5, 112-120.
104. Han, M. H., Hwang, S. I., Roy, D. B., Lundgren, D. H. et al., Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Nature 2008, 451, 1076-1081.
105. Ly, L., Barnett, M., Zheng, Y. Z., Gulati, T. et al., A comprehensive tissue processing method for quantitative proteomics of formalin-fixed multiple sclerosis lesions. J. Proteome Res. 2011, 10, 4855-4868.
106. Jastorff, A. M., Haegler, K., Maccarrone, G., Holsboer, F. et al., Regulation of proteins mediating neurodegeneration in experimental autoimmune encephalomyelitis and multiple sclerosis. Proteomics Clin. Appl. 2009, 3, 1273-1287.
107. Linker, R. A., Brechlin, P., Jesse, S., Steinacker, P. et al., Proteome profiling in murine models of multiple sclerosis: identification of stage specific markers and culprits for tissue damage. PLoS One 2009, 4, e7624.
108. Vanheel, A., Daniels, R., Plaisance, S., Baeten, K. et al., Identification of protein networks involved in the disease course of experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis. PLoS One 2012, 7, e35544.
109. Liu, T., Donahue, K. C., Hu, J., Kurnellas, M. P. et al., Identification of differentially expressed proteins in experimental autoimmune encephalomyelitis (EAE) by proteomic analysis of the spinal cord. J. Proteome Res. 2007, 6, 2565-2575.
110. Jain, M. R., Bian, S., Liu, T., Hu, J. et al., Altered proteolytic events in experimental autoimmune encephalomyelitis discovered by iTRAQ shotgun proteomics analysis of spinal cord. Proteome Sci. 2009, 7, 25.
111. Rosenling, T., Stoop, M., Attali, A., van Aken, H. et al., Profiling and identification of cerebrospinal fluid proteins in a rat EAE model of multiple sclerosis. J. Proteome Res. 2012, 11, 2048-2060.
112. Anderson, N. L., Anderson, N. G., The human plasma proteome: history, character, and diagnostic prospects. Mol. Cell Proteomics 2002, 1, 845-867.
113. Qian, W. J., Jacobs, J. M., Liu, T., Camp, D. G., 2nd, Smith, R. D., Advances and challenges in liquid chromatography-mass spectrometry-based proteomics profiling for clinical applications. Mol. Cell Proteomics 2006, 5, 1727-1744.
114. Schiess, R., Wollscheid, B., Aebersold, R., Targeted proteomic strategy for clinical biomarker discovery. Mol. Oncol. 2009, 3, 33-44.
115. Lee, H. J., Lee, E. Y., Kwon, M. S., Paik, Y. K., Biomarker discovery from the plasma proteome using multidimensional fractionation proteomics. Curr. Opin. Chem. Biol. 2006, 10, 42-49.
116. McComb, J. G., Recent research into the nature of cerebrospinal fluid formation and absorption. J. Neurosurg. 1983, 59, 369-383.
117. Johanson, C. E., Preston, J. E., Chodobski, A., Stopa, E. G. et al., AVP V1 receptor-mediated decrease in Cl-efflux and increase in dark cell number in choroid plexus epithelium. Am. J. Physiol. 1999, 276, C82-C90.
118. Nilsson, C., Lindvall-Axelsson, M., Owman, C., Neuroendocrine regulatory mechanisms in the choroid plexus-cerebrospinal fluid system. Brain Res. Rev. 1992, 17, 109-138.
119. Oreskovic, D., Klarica, M., The formation of cerebrospinal fluid: nearly a hundred years of interpretations and misinterpretations. Brain Res. Rev. 2010, 64, 241-262.
120. Cutler, R. W., Page, L., Galicich, J., Watters, G. V., Formation and absorption of cerebrospinal fluid in man. Brain 1968, 91, 707-720.
121. Yuan, X., Desiderio, D. M., Proteomics analysis of human cerebrospinal fluid. J. Chromatogr. 2005, 815, 179-189.
122. Thompson, E. J., Proteins of the Cerebrospinal Fluid : analysis and Interpretation in the Diagnosis and Treatment of Neurological Diseases, Elsevier, Boston, MA 2005.
123. Risau, W., Wolburg, H., Development of the blood-brain barrier. Trends Neurosci. 1990, 13, 174-178.
124. Hawkins, B. T., Davis, T. P., The blood-brain barrier/neurovascular unit in health and disease. Pharmacol. Rev. 2005, 57, 173-185.
125. Wolburg, H., Lippoldt, A., Tight junctions of the blood-brain barrier: development, composition and regulation. Vascul. Pharmacol. 2002, 38, 323-337.
126. Abbott, N. J., Evidence for bulk flow of brain interstitial fluid: significance for physiology and pathology. Neurochem. Int. 2004, 45, 545-552.
127. Felgenhauer, K., Evaluation of molecular size by gel electrophoretic techniques. Hoppe Seylers Z Physiol. Chem. 1974, 355, 1281-1290.
128. Link, H., Tibbling, G., Principles of albumin and IgG analyses in neurological disorders. III. Evaluation of IgG synthesis within the central nervous system in multiple sclerosis. Scand. J. Clin. Lab. Invest. 1977, 37, 397-401.
129. Tourtellotte, W. W., Potvin, A. R., Baumhefner, R. W., Potvin, J. H. et al., Multiple sclerosis de novo CNS IgG synthesis. Effect of CNS irradiation. Arch. Neurol. 1980, 37, 620-624.
130. Reiber, H., Flow rate of cerebrospinal fluid (CSF)-a concept common to normal blood-CSF barrier function and to dysfunction in neurological diseases. J. Neurol. Sci. 1994, 122, 189-203.
131. Zhang, J., Goodlett, D. R., Peskind, E. R., Quinn, J. F. et al., Quantitative proteomic analysis of age-related changes in human cerebrospinal fluid. Neurobiol. Aging 2005, 26, 207-227.
132. Nilsson, C., Stahlberg, F., Thomsen, C., Henriksen, O. et al., Circadian variation in human cerebrospinal fluid production measured by magnetic resonance imaging. Am. J. Physiol. 1992, 262, R20-R24.
133. Wolburg-Buchholz, K., Mack, A. F., Steiner, E., Pfeiffer, F. et al., Loss of astrocyte polarity marks blood-brain barrier impairment during experimental autoimmune encephalomyelitis. Acta Neuropathol. 2009, 118, 219-233.
134. Minagar, A., Alexander, J. S., Blood-brain barrier disruption in multiple sclerosis. Mult. Scler. 2003, 9, 540-549.
135. Blennow, K., Fredman, P., Wallin, A., Gottfries, C. G. et al., Protein analysis in cerebrospinal fluid. II. Reference values derived from healthy individuals 18-88 years of age. Eur. Neurol. 1993, 33, 129-133.
136. Maurer, M. H., Proteomics of brain extracellular fluid (ECF) and cerebrospinal fluid (CSF). Mass Spectrom. Rev. 2010, 29, 17-28.
137. Stadelmann, C., Wegner, C., Bruck, W., Inflammation, demyelination, and degeneration - recent insights from MS pathology. Biochim. Biophys. Acta 2011, 1812, 275-282.
138. Lucchinetti, C., Bruck, W., Parisi, J., Scheithauer, B. et al., Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 2000, 47, 707-717.
139. Filippi, M., Campi, A., Dousset, V., Baratti, C. et al., A magnetization transfer imaging study of normal-appearing white matter in multiple sclerosis. Neurology 1995, 45, 478-482.
140. Filippi, M., Rocca, M. A., Martino, G., Horsfield, M. A., Comi, G., Magnetization transfer changes in the normal appearing white matter precede the appearance of enhancing lesions in patients with multiple sclerosis. Ann. Neurol. 1998, 43, 809-814.
141. Graumann, U., Reynolds, R., Steck, A. J., Schaeren-Wiemers, N., Molecular changes in normal appearing white matter in multiple sclerosis are characteristic of neuroprotective mechanisms against hypoxic insult. Brain Pathol. 2003, 13, 554-573.
142. Lindberg, R. L., De Groot, C. J., Certa, U., Ravid, R. et al., Multiple sclerosis as a generalized CNS disease-comparative microarray analysis of normal appearing white matter and lesions in secondary progressive MS. J. Neuroimmunol. 2004, 152, 154-167.
143. de Sousa Abreu, R., Penalva, L. O., Marcotte, E. M., Vogel, C., Global signatures of protein and mRNA expression levels. Mol. Biosyst. 2009, 5, 1512-1526.
144. Guo, Y., Fu, Z., Van Eyk, J. E., A proteomic primer for the clinician. Proc. Am. Thorac. Soc. 2007, 4, 9-17.
145. Makawita, S., Diamandis, E. P., The bottleneck in the cancer biomarker pipeline and protein quantification through mass spectrometry-based approaches: current strategies for candidate verification. Clin. Chem. 2010, 56, 212-222.
146. Issaq, H. J., Veenstra, T. D., Would you prefer multiple reaction monitoring or antibodies with your biomarker validation? Expert Rev. Proteomics 2008, 5, 761-763.
147. Lange, V., Picotti, P., Domon, B., Aebersold, R., Selected reaction monitoring for quantitative proteomics: a tutorial. Mol. Syst. Biol. 2008, 4, 222-235.
148. Picotti, P., Aebersold, R., Selected reaction monitoring-based proteomics: workflows, potential, pitfalls and future directions. Nat. Methods 2012, 9, 555-566.
149. Rifai, N., Gillette, M. A., Carr, S. A., Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat. Biotechnol. 2006, 24, 971-983.
150. Anderson, L., Hunter, C. L., Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol. Cell Proteomics 2006, 5, 573-588.
151. Kuzyk, M. A., Smith, D., Yang, J., Cross, T. J. et al., Multiple reaction monitoring-based, multiplexed, absolute quantitation of 45 proteins in human plasma. Mol. Cell Proteomics 2009, 8, 1860-1877.
152. Addona, T. A., Abbatiello, S. E., Schilling, B., Skates, S. J. et al., Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat. Biotechnol. 2009, 27, 633-641.
153. Keshishian, H., Addona, T., Burgess, M., Kuhn, E., Carr, S. A., Quantitative, multiplexed assays for low abundance proteins in plasma by targeted mass spectrometry and stable isotope dilution. Mol. Cell Proteomics 2007, 6, 2212-2229.
154. Fortin, T., Salvador, A., Charrier, J. P., Lenz, C. et al., Clinical quantitation of prostate-specific antigen biomarker in the low nanogram/milliliter range by conventional bore liquid chromatography-tandem mass spectrometry (multiple reaction monitoring) coupling and correlation with ELISA tests. Mol. Cell Proteomics 2009, 8, 1006-1015.
155. Kuhn, E., Addona, T., Keshishian, H., Burgess, M. et al., Developing multiplexed assays for troponin I and interleukin-33 in plasma by peptide immunoaffinity enrichment and targeted mass spectrometry. Clin. Chem. 2009, 55, 1108-1117.
156. Han, B., Higgs, R. E., Proteomics: from hypothesis to quantitative assay on a single platform. Guidelines for developing MRM assays using ion trap mass spectrometers. Brief Funct. Genomic Proteomic. 2008, 7, 340-354.
157. Picotti, P., Rinner, O., Stallmach, R., Dautel, F. et al., High-throughput generation of selected reaction-monitoring assays for proteins and proteomes. Nat. Methods 2010, 7, 43-46.
158. Stergachis, A. B., MacLean, B., Lee, K., Stamatoyannopoulos, J. A., MacCoss, M. J., Rapid empirical discovery of optimal peptides for targeted proteomics. Nat. Methods 2011, 8, 1041-1043.
159. Lange, V., Malmstrom, J. A., Didion, J., King, N. L. et al., Targeted quantitative analysis of Streptococcus pyogenes virulence factors by multiple reaction monitoring. Mol. Cell Proteomics 2008, 7, 1489-1500.
160. Maclean, B., Tomazela, D. M., Shulman, N., Chambers, M. et al., Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics 2010, 26, 966-968.
161. Jia, Y., Wu, T., Jelinek, C. A., Bielekova, B. et al., Development of protein biomarkers in cerebrospinal fluid for secondary progressive multiple sclerosis using selected reaction monitoring mass spectrometry (SRM-MS). Clin. Proteomics 2012, 9, 9-17.
162. Rezeli, M., Vegvari, A., Ottervald, J., Olsson, T. et al., MRM assay for quantitation of complement components in human blood plasma - a feasibility study on multiple sclerosis. J. Proteomics 2011, 1, 9-17.
163. Picotti, P., Bodenmiller, B., Mueller, L. N., Domon, B., Aebersold, R., Full dynamic range proteome analysis of S. cerevisiae by targeted proteomics. Cell 2009, 138, 795-806.
164. Stahl-Zeng, J., Lange, V., Ossola, R., Eckhardt, K. et al., High sensitivity detection of plasma proteins by multiple reaction monitoring of N-glycosites. Mol. Cell Proteomics 2007, 6, 1809-1817.
165. Sawcer, S., Hellenthal, G., Pirinen, M., Spencer, C. C. et al., Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011, 476, 214-219.
166. Lock, C., Hermans, G., Pedotti, R., Brendolan, A. et al., Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat. Med. 2002, 8, 500-508.
167. Mix, E., Ibrahim, S., Pahnke, J., Koczan, D. et al., Gene-expression profiling of the early stages of MOG-induced EAE proves EAE-resistance as an active process. J. Neuroimmunol. 2004, 151, 158-170.
168. Baranzini, S. E., Bernard, C. C., Oksenberg, J. R., Modular transcriptional activity characterizes the initiation and progression of autoimmune encephalomyelitis. J. Immunol. 2005, 174, 7412-7422.
169. Blanchet, L., Smolinska, A., Attali, A., Stoop, M. P. et al., Fusion of metabolomics and proteomics data for biomarkers discovery: case study on the experimental autoimmune encephalomyelitis. BMC Bioinformatics 2011, 12, 254-265.
170. Noga, M. J., Dane, A., Shi, S., Attali, A. et al., Metabolomics of cerebrospinal fluid reveals changes in the central nervous system metabolism in a rat model of multiple sclerosis. Metabolomics 2012, 8, 253-263.
171. Villoslada, P., Baranzini, S., Data integration and systems biology approaches for biomarker discovery: challenges and opportunities for multiple sclerosis. J. Neuroimmunol. 2012, 248, 58-65.
172. Satoh, J. I., Tabunoki, H., Yamamura, T., Molecular network of the comprehensive multiple sclerosis brain-lesion proteome. Mult. Scler. 2009, 15, 531-541.
173. Han, M. H., Lundgren, D. H., Jaiswal, S., Chao, M. et al., Janus-like opposing roles of CD47 in autoimmune brain inflammation in humans and mice. J. Exp. Med. 2012, 209, 1325-1334.
174. Bauch, A., Superti-Furga, G., Charting protein complexes, signaling pathways, and networks in the immune system. Immunol. Rev. 2006, 210, 187-207.
175. Hwang, D., Rust, A. G., Ramsey, S., Smith, J. J. et al., A data integration methodology for systems biology. Proc. Natl. Acad. Sci. USA 2005, 102, 17296-17301.
176. Villoslada, P., Steinman, L., Baranzini, S. E., Systems biology and its application to the understanding of neurological diseases. Ann. Neurol. 2009, 65, 124-139.
177. Ilyin, S. E., Belkowski, S. M., Plata-Salaman, C. R., Biomarker discovery and validation: technologies and integrative approaches. Trends Biotechnol. 2004, 22, 411-416.
178. Teunissen, C. E., Petzold, A., Bennett, J. L., Berven, F. S. et al., A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology 2009, 73, 1914-1922.
179. Teunissen, C. E., Tumani, H., Bennett, J. L., Berven, F. S. et al., Consensus guidelines for CSF and blood biobanking for CNS biomarker studies. Mult. Scler. Int. 2011, 2011, 246412-246420.
180. Wipfler, P., Heikkinen, A., Harrer, A., Pilz, G. et al., Circadian rhythmicity of inflammatory serum parameters: a neglected issue in the search of biomarkers in multiple sclerosis. J. Neurol. 2012.
181. Mischak, H., Allmaier, G., Apweiler, R., Attwood, T. et al., Recommendations for biomarker identification and qualification in clinical proteomics. Sci. Transl. Med. 2010, 2, 46ps42.
182. Svensson, M., Boren, M., Skold, K., Falth, M. et al., Heat stabilization of the tissue proteome: a new technology for improved proteomics. J. Proteome Res. 2009, 8, 974-981.
183. Kroksveen, A. C., Opsahl, J. A., Aye, T. T., Ulvik, R. J., Berven, F. S., Proteomics of human cerebrospinal fluid: discovery and verification of biomarker candidates in neurodegenerative diseases using quantitative proteomics. J. Proteomics 2011, 74, 371-388.
184. Harris, V. K., Diamanduros, A., Good, P., Zakin, E. et al., Bri2-23 is a potential cerebrospinal fluid biomarker in multiple sclerosis. Neurobiol. Dis. 2010, 40, 331-339.
185. Farias, A. S., Martins-de-Souza, D., Guimaraes, L., Pradella, F. et al., Proteome analysis of spinal cord during the clinical course of monophasic experimental autoimmune encephalomyelitis. Proteomics 2012, 12, 2656-2662.
186. Rithidech, K. N., Honikel, L., Milazzo, M., Madigan, D. et al., Protein expression profiles in pediatric multiple sclerosis: potential biomarkers. Mult. Scler. 2009, 15, 455-464.
187. Fainardi, E., Castellazzi, M., Tamborino, C., Trentini, A. et al., Potential relevance of cerebrospinal fluid and serum levels and intrathecal synthesis of active matrix metalloproteinase-2 (MMP-2) as markers of disease remission in patients with multiple sclerosis. Mult. Scler. 2009, 15, 547-554.